RHHBY

Obesity: The Next Investment Driver

By James Brumley, InvestorPlace Feature Writer
The global market for weight-control products of all types is forecast to hit $53 billion in just five years, and several companies are primed to profit.

Feel Safe Scooping Up Swiss Stocks

By Charles Sizemore, Principal of Sizemore Capital
There's a lot to like about Switzerland as an investment haven. It's not a perfect environment, but a number of Swiss stocks look promising right now.

Cue the Biotech M&A Attack!

By Gene Marcial, InvestorPlace Contributor
A rush of buyout activity in biotechs like Human Genome and Illumina could produce more frenzied M&A deals down the road.

3 New Biotech Buys for Your Portfolio

By Louis Navellier, Editor, Growth Investor
Three new biotech buys lead the way for additions to your portfolio as we head into April.

Analysts Run the Apple Asylum — Tuesday’s IP Market Recap

By Kyle Woodley, Senior Investing Editor, Kiplinger
Price targets keep climbing to the moon: $715, $910 -- even $1,001.

Here Comes a Bidding War for Amylin

By Gene Marcial, InvestorPlace Contributor
Approval of its diabetes drug has Big Pharma banging on its door, with Bristol-Myers Squibb already said to have offered $3.5 billion, or $22 per share.

Generic Versions of Boniva Approved By the FDA

By InvestorPlace Staff
The FDA approved the first generic versions of osteoporosis drug Boniva, allowing manufacturers like Apotex, Orchid Healthcare and Mylan to make the drug.

Breaking Down Societe Generale’s Top 40 Dividend Stocks in the World

By Kyle Woodley, Senior Investing Editor, Kiplinger
Societe Generale recently put out its annual list of the top 40 dividend payers across the globe. Here's a look at those companies, as well as a few trends.

Why Illumina’s Future Remains Bright

By Gene Marcial, InvestorPlace Contributor
Rejection of Roche's takeover bid has cooled ILMN shares, but many expect Roche to step up its advances. If not, Illumina still has great growth prospects.

Amylin Gets a Boost From Its Diabetes Drug Approval

By Barry Cohen, Health Care Writer
FDA approval of Bydureon -- a once-a-week injectable drug -- could make Amylin a takeover target for a Big Pharma.

14,849% Profits in Red-Hot Penny Stocks! … Or Go Bankrupt

By Jeff Reeves
Penny stock investment scams and over-hyped newsletters dangle the prospect of profits, but these cheap stocks are nothing but risky speculations.

Illumina Sparks Mean Gene Rally — Wednesday’s IP Market Recap

By Kyle Woodley, Senior Investing Editor, Kiplinger
A hostile offer from Roche warms investors' hearts.

Roche’s Hostile Bid for Illumina Could Reach $60 Per Share

By Barry Cohen, Health Care Writer
Swiss health care giant Roche made a hostile bid to buy Illumina for $44.50 per share, but many think that number will be higher when all is said and done.
Load More